Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona

• Published in: PloS one Vol. 11; no. 4; p. e0153076
• Main Authors: Riu, Marta, Chiarello, Pietro, Terradas, Roser, Sala, Maria, Garcia-Alzorriz, Enric, Castells, Xavier, Grau, Santiago, Cots, Francesc
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.04.2016; Public Library of Science (PLoS)
• Subjects: Accounting; Aged; Aged, 80 and over; Antibiotics; Antiinfectives and antibacterials; Bacteremia; Bacteremia - economics; Bacteremia - microbiology; Bacteremia - therapy; Bacteria; Bias; Biology and Life Sciences; Catheters; Causes of; Cost analysis; Costs and Cost Analysis; Criteria; Cross Infection - economics; Cross Infection - microbiology; Cross Infection - therapy; Drug resistance; E coli; Econometrics; Economic aspects; Escherichia coli; Female; Health care costs; Hospitalization - economics; Hospitals; Hospitals, Teaching; Humans; Klebsiella; Male; Medicine and Health Sciences; Microorganisms; Middle Aged; Mortality; Multidrug resistance; Nosocomial infection; Nosocomial infections; Patients; Pseudomonas aeruginosa; Regression analysis; Regression models; Retrospective Studies; Sensitivity; Sensitivity analysis; Spain; Staphylococcus aureus; Statistical analysis; Spain
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0153076

To calculate the incremental cost of nosocomial bacteremia caused by the most common organisms, classified by their antimicrobial susceptibility. We selected patients who developed nosocomial bacteremia caused by Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa. These microorganisms were analyzed because of their high prevalence and they frequently present multidrug resistance. A control group consisted of patients classified within the same all-patient refined-diagnosis related group without bacteremia. Our hospital has an established cost accounting system (full-costing) that uses activity-based criteria to analyze cost distribution. A logistic regression model was fitted to estimate the probability of developing bacteremia for each admission (propensity score) and was used for propensity score matching adjustment. Subsequently, the propensity score was included in an econometric model to adjust the incremental cost of patients who developed bacteremia, as well as differences in this cost, depending on whether the microorganism was multidrug-resistant or multidrug-sensitive. A total of 571 admissions with bacteremia matched the inclusion criteria and 82,022 were included in the control group. The mean cost was € 25,891 for admissions with bacteremia and € 6,750 for those without bacteremia. The mean incremental cost was estimated at € 15,151 (CI, € 11,570 to € 18,733). Multidrug-resistant P. aeruginosa bacteremia had the highest mean incremental cost, € 44,709 (CI, € 34,559 to € 54,859). Antimicrobial-susceptible E. coli nosocomial bacteremia had the lowest mean incremental cost, € 10,481 (CI, € 8,752 to € 12,210). Despite their lower cost, episodes of antimicrobial-susceptible E. coli nosocomial bacteremia had a major impact due to their high frequency. Adjustment of hospital cost according to the organism causing bacteremia and antibiotic sensitivity could improve prevention strategies and allow their prioritization according to their overall impact and costs. Infection reduction is a strategy to reduce resistance.